<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene L5F;T95I;D253G;S477N;D614G;A701V literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.L5F;T95I;D253G;S477N;D614G;A701V</span> literature reference collection</h1>
<div class="effect_section"><h2 id="convalescent_plasma_binding">Convalescent plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Subtype of the B.1.526 "New York" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera.<br/> (<a href="https://doi.org/10.1101/2021.03.24.436620" class="lit_link">Zhou et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Subtype of the B.1.526 "New York" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.<br/> (<a href="https://doi.org/10.1101/2021.03.24.436620" class="lit_link">Zhou et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.<br/> (<a href="https://doi.org/10.1101/2021.06.28.449914" class="lit_link">Choi et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
